Immunotherapy shot targets Pre-Cancer mouth spots
NCT ID NCT05327270
First seen Jan 07, 2026 · Last updated Apr 25, 2026 · Updated 14 times
Summary
This early-stage study tests whether injecting the immunotherapy drug nivolumab directly into high-risk oral premalignant lesions (abnormal spots in the mouth that could become cancer) is safe and can shrink or eliminate them. 18 adults with such lesions are receiving the injections. The goal is to prevent progression to head and neck cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.